Mereo BioPharma up on promising interim data from cancer study

Mereo BioPharma

30/11/2021 13:31

** U.S.-listed shares of Mereo BioPharma  MREO.O  rise 1.6%
to $1.84 premarket
    ** Co reports promising interim data from clinical study
testing its experimental drug, etigilimab, in combination with
Bristol Myers Squibb's  BMY.N  cancer therapy Opdivo in certain
solid tumors  urn:newsml:reuters.com:*:nGNX4PgK2f
    ** As of the cut-off date, study showed one complete
response in cervical cancer, one partial response in ovarian
cancer and four instances of stable disease in ovarian cancer,
cervical cancer, and uveal melanoma - MREO
    ** Drug combination has been safe and well tolerated, with
no new safety signals
    ** Stock down 49.4% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))